Vaishali Pharma Ltd. · NSE:VAISHALI
Vaishali Pharma — Q2 FY24 Earnings Presentation
39 slides from Vaishali Pharma's earnings presentation, Nov 28, 2023
Slide 1: Exchange filing cover letter under Regulation 30
November 28, 2023 To, The Manager National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051 Stock Code: VAISHALI ISIN: INE972X01014 SUB: Announcement under Regulation 30 of Securities and Exchange Board of India (
Slide 2: Vaishali Pharma Limited Q2 FY24 Investor Presentation
Vaishali Pharma Limited Q2 FY24 Investor Presentation
Slide 3: Safe Harbour Statement
Safe Harbour Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Vaishali Pharma Limited (‘Vaishali Pharma’, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for a
Slide 4: Company Overview
Company Overview
Slide 5: A Glimpse Into Vaishali Pharma
A Glimpse Into Vaishali Pharma Incorporated in 1989, Vaishali Pharma Limited (‘Vaishali Pharma’, The Company), Mumbai based company has firmly established itself in the pharmaceutical sector, specializing in the production and marketing of Active Pharmaceutical Ingredients (APIs), Formulation, surgi
Slide 6: Essential Insights
Essential Insights 40+ 35+ 1,000+ Countries Years of Experience Customers 1,500+ 250+ 35+ Products Brands Locations WHO-GMP, Over 100 FY23 EU-GMP & Tonnes Revenue - ₹ 69.66 Cr Warehouse Capacity USFDA Approved EBITDA - ₹ 11.36 Cr Manufacturing PAT - ₹ 6.60 Cr Facilities Investor Presentation 5
Slide 7: Guiding Principles: Mission, Vision, & Values
Guiding Principles: Mission, Vision, & Values "To be a well recognised Indian MNC in the pharmaceuticals and healthcare industry” VISION "To contribute substantially towards well-being and health of the society by providing high quality products and service” MISSION Total quality management Providin
Slide 8: The Evolution: Timeline Of Vaishali Pharma
The Evolution: Timeline Of Vaishali Pharma 1989 1994 2000 2008 2009 2011 2012 Inception as Vaishali Joint venture with Expanded presence Rebranded to Vaishali Remarkable 80% Expanded overseas with Ventured into Pharmachem, an Arochem Industries, with a new office in Pharma Pvt Ltd. Achieved growth i
Slide 9: A Testament To Standards
A Testament To Standards Company Certifications Surgical Certifications ISO 9001 : 2015 ISO 13484 : 2016 Conformitè Europëenne Investor Presentation 8
Slide 10: A Testament To Standards: Global Certifications
A Testament To Standards: Global Certifications Formulation Certifications ">' ollo.JG" M INISTRY OF H EALTH MOHYEMEN _____________________________________ 1. ____________________________________ 1. ____________________________________ L ___________________________________ _ • '''-+''*'I I..'. ;' ''
Slide 11: Servicing Clients Across The Globe
Servicing Clients Across The Globe Russia U.K Kazakhstan Armenia Kyrgyzstan Uzbekistan Turkey Tajikistan Turkmenistan Morocco Jordan Iraq Iran Afghanistan Egypt UAE Myanmar Oman Sudan Philippines Guatemala Nicaragua Yemen Thailand Vietnam Nigeria Costa Rica Cameroon colombia Ethiopia Sri Lanka Cambo
Slide 12: Core Competencies
Core Competencies Global Presence Strong Relations Strong Product Portfolio Vaishali Pharma boasts an expansive The Company has consistently maintained Vaishali Pharma offers a varied and premium operation that stretches across multiple strong, enduring relations with suppliers and selection of prod
Slide 13: Management Team Overview
Management Team Overview
Slide 14: Key Managerial Personnel
Key Managerial Personnel Mr. Atul Vasani Mr. Dewansh Vasani Chairman & Managing Director Executive Director • With over 30 years of experience in pharmaceutical sector, he • He is responsible for purchase management boasts an impressive track record and a dynamic business sense. • He excels in coord
Slide 15: Key Managerial Personnel
Key Managerial Personnel Ms. Priyanka Vasani Dr. Prafulla Nandi Chief Operating Officer Chief technical officer • He has 30+ years' experience in Pharmaceutical Research & Global • With a decade of invaluable experience in managing operations and Regulatory Affairs. He holds a Master's from BITS, Pi
Slide 16: Business Overview
Business Overview
Slide 17: Business Framework: Domestic & Exports
Business Framework: Domestic & Exports o Manufacturing & Export • Pharmaceutical Formulations Contract Manufacturing & • Surgical Products Trading of APIs • Veterinary Products Supply of APIs for Export Captive • Herbal & Nutraceuticals Consumption Products Domestic Export o Exports of APIs Investor
Slide 18: A Spectrum Of Offerings: Product Portfolio
A Spectrum Of Offerings: Product Portfolio API Products Formulation Products Surgical Products Veterinary Products Nutraceutical Products Oncology Products Investor Presentation 17
Slide 19: Exploring Product Portfolio
Exploring Product Portfolio API and Formulation Products API is the primary component that gives a drug its therapeutic effect. On the other hand, a finished formulation or a formulation intermediate involves a combination of chemicals, including the active ingredients, mixed in precise proportions
Slide 20: Exploring Product Portfolio
Exploring Product Portfolio Veterinary Products Veterinary products play an important role in preventing and managing animal diseases. Vaishali Pharma is dedicated to marketing these products, ensuring high- quality veterinary medications are accessible to all at reasonable prices. Bolus Injection P
Slide 21: Introducing New Products
Introducing New Products Sedatives and Hypnotics Vitamin C and Antifungals Nutraceutical Sprays Dexmedetomidine 100 mcg/ml Vitamin C Effervescent Tablets Folic Acid + Vitamin B12 spray Chewable Ascorbic Acid Tablets with Zinc Orange Propofol 1% Vitamin D3 Spray Flavour Chewable Ascorbic Acid Tablets
Slide 22: Product Wise Revenue Breakup
Product Wise Revenue Breakup FY23 In % FY22 In % 10 10 15 15 50 55 20 25 Formulation API Surgical Veterinary Nutraceutical Investor Presentation 21
Slide 23: Industry Overview
Industry Overview
Slide 24: Global Market Dynamics
Global Market Dynamics Surpassing the trillion-dollar mark, the global pharmaceutical landscape is evolving rapidly, with emerging markets and driving towards a healthier future by 2028 Geographically, the In 2023, the global United States stands out Looking forward, the pharmaceutical market as the
Slide 25: Government Initiatives And Schemes
Government Initiatives And Schemes India's Pharma Sector Boom: Targeting US$ 130 Billion by 2030 with CAGR of over 10% In US$ Billion ➢ India's pharmaceutical industry projected to reach US$ 65 billion by 2024 and around US$ 130 Indian Pharmaceutical Market billion by 2030. Currently, the industry i
Slide 26: Government Initiatives And Schemes
Government Initiatives And Schemes India accelerates healthcare innovation, emphasizing digital health records, pharmaceutical industry growth, and expanded access to affordable medicines. In US$ Billion Government Expenditure on Health in India As per the Union Budget 2023-24 A mission is set to el
Slide 27: Indian Pharma: FDI Boost, Global Reach, And PLI Strategy
Indian Pharma: FDI Boost, Global Reach, And PLI Strategy Bolstering India's Pharmaceutical Industry Growth and Self-reliance Production Linked Incentive (PLI) - In June 2021, Finance Minister Ms. Increase in Investment - 100% FDI is permitted for Greenfield Nirmala Sitharaman designated an extra out
Slide 28: Financial Overview
Financial Overview
Slide 29: Q2 FY24 Performance Highlights
Q2 FY24 Performance Highlights Total Income EBITDA & PAT EBITDA Margin & PAT Margin EBITDA PAT EBITDA% PAT% 3.32 2.95 23.90 13.89 22.97 12.86 1.99 1.70 14.33 13.24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Q2 FY23 Q2 FY24 Amount In ₹ Cr & Margin in % Investor Presentation 28
Slide 30: Last Four Quarter Performance
Last Four Quarter Performance In ₹ Cr Particular Q2 FY24 Q1 FY24 Q4 FY23 Q3 FY23 Q2 FY23 Revenue 12.57 13.42 26.24 20.09 13.16 Other Income 0.30 0.36 0.53 0.53 0.73 Total Income 12.86 13.78 26.77 20.62 13.89 Total Expenditure 9.91 11.11 25.46 16.53 10.57 EBITDA 2.95 2.67 1.31 4.08 3.32 Interest 0.47
Slide 31: Financial Snapshot
Financial Snapshot Total Income EBITDA & EBITDA Margin PAT & PAT Margin EBITDA EBITDA % PAT PAT % 77.61 9.18 71.89 15.8 55.58 6.60 11.14 11.36 5.19 8.64 7.99 4.02 4.44 1.88 1.05 FY21 FY22 FY23 FY21 FY22 FY23 FY21 FY22 FY23 All Figures In ₹ Cr Investor Presentation 30
Slide 32: Financial Snapshot
Financial Snapshot ROE (In %) ROCE (In %) 16.29 19.71 15.27 17.36 9.98 4.67 FY21 FY22 FY23 FY21 FY22 FY23 Debt to Equity (In Times) Interest Coverage (In Times) 0.78 0.79 5.40 3.33 0.34 1.54 FY21 FY22 FY23 FY21 FY22 FY23 Investor Presentation 31
Slide 33: Profit & Loss Statement
Profit & Loss Statement In ₹ Cr Particular FY23 FY22 FY21 Revenues 69.66 75.82 53.77 Other Income 2.23 1.79 1.81 Total Income 71.89 77.61 55.58 Raw Material Costs 54.68 63.50 46.15 Employee Costs 2.08 2.10 1.85 Other Expenses 3.77 3.37 3.14 Total Expenditure 60.53 68.97 51.14 EBITDA 11.36 8.64 4.44
Slide 34: Balance Sheet
Balance Sheet In ₹ Cr Equities & Liabilities FY23 FY22 FY21 Assets FY23 FY22 FY21 Equity 10.55 10.55 10.55 Non Current Assets Reserves 29.99 15.81 11.87 Fixed Assets 2.65 1.67 1.26 Net Worth 40.53 26.35 22.42 Non Current Investments 0.43 0.43 0.43 Non Current Liabilities Other Non Current Financial
Slide 35: Cash Flow Statement
Cash Flow Statement In ₹ Cr Particular FY21 FY22 FY23 Cashflow from Operations 2.01 1.32 1.08 Cashflow from Investments -0.11 -0.85 0.28 Cashflow from Financing -1.81 0.42 -1.73 Net Cash flow 0.09 0.89 -0.37 Opening Cash Balance 0.38 0.47 1.36 Closing Cash Balance 0.47 1.36 0.98 Investor Presentatio
Slide 36: Stock Data
Stock Data NSE: VAISHALI ISIN: INE972X01014 SHARE HOLDING PATTERN As on 30-09-2023 As on 24-11-2023 Share Price (₹) 136.00 Market Capitalization (₹ Cr) 144.11 26.74% Promoter & Promoter Group No. of Shares Outstanding 1,05,96,213 Public Face Value (₹) 10 73.26% 52 week High-Low (₹) 193.75 – 112.10 S
Slide 37: The Way Ahead
The Way Ahead
Slide 38: Future Growth Drivers
Future Growth Drivers Core Focus on Geographic Expansion: Diversifying Product Boosting Production Nutraceutical Products: Portfolio: Capacity: In the evolving landscape of Vaishali Pharma is ambitiously Recognizing the vast opportunities Vaishali Pharma intends to boost its healthcare and wellness,
Slide 39: Thank You
Vaishali Pharma Limited 706-709, Aravalli Business Center, R.C. Patel Road, Off Sodawala Lane, Borivali (West), Mumbai-400092. Phone: +91 22 42171819 (30Lines) Email: sales@vaishalipharma.com Website: www.vaishalipharma.com Kirin Advisors Private Limited 713-B, Lodha Supremus II, Wagle Estate, Thane